5.72
5.72 (0%)
As of Dec 26, 2024
Abeona Therapeutics Inc. [ABEO]
Source:
Company Overview
Abeona Therapeutics Inc., a Delaware corporation is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threateningdiseases. Our lead clinical program is for prademagene zamikeracel (“pz-cel”), an autologous, cell-based gene therapy currentlyin development for recessive dystrophic epidermolysis bullosa (“RDEB”).
| Country | United States |
| Headquarters | cleveland, ohio |
| Phone Number | 646-813-4701 |
| Industry | manufacturing |
| CEO | Vishwas Seshadri |
| Website | www.abeonatherapeutics.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-64.2 |
| Net Income | $-63.7 |
| Net Cash | $8.9 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -73.7% |
| Profit as % of Stockholder Equity | -144.8% |
Management Effectiveness
| Return on Equity | -144.8% |
| Return on Assets | -58.5% |
| Turnover Ratio | |
| EBITA | $-64.2 |
Balance Sheet and Cash Flow Measures
| Total Assets | $108.9 |
| Total Liabilities | $64.9 |
| Operating Cash Flow | $-56 |
| Investing Cash Flow | $-39.2 |
| Financing Cash Flow | $104.1 |
